<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722212</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01473-50</org_study_id>
    <nct_id>NCT03722212</nct_id>
  </id_info>
  <brief_title>Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test</brief_title>
  <acronym>METAglut1</acronym>
  <official_title>Evaluation of METAglut1 Diagnostic Test Performances in Patients With a Clinical Suspicion of GLUT1 Deficiency Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>METAFORA biosystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cemka-Eval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French National Authority for Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>METAFORA biosystems</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at validating the diagnostic performances of the METAglut1, a blood in vitro
      diagnostic test, for the simple and early diagnosis of the GLUT1 deficiency syndrome
      (GLUT1DS, or De Vivo disease).

      The blood test will be carried out prospectively on patients presenting with a clinical
      suspicion of GLUT1DS, blindly from the reference strategy, which consists in a lumbar
      puncture for glycorrhachia measurement, completed by a molecular analysis.

      The study will be conducted in more than 40 centers in France on up to 3,000 patients for 2
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GLUT1 Deficiency Syndrome (GLUT1-DS) is a debilitating, proteiform neurometabolic
      disorder caused by an impairment in the glucose transporter GLUT1 at the cell surface.
      Patients suffer from seizures, movement disorders and intellectual disabilities. A timely
      diagnosis is of prime importance as this haploinsufficiency can be improved by the so-called
      ketogenic diet.

      By diagnosing GLUT1-DS early, based on symptoms associated with GLUT1-DS, healthcare
      providers can prescribe the Keto diet therapy early in the disease progression, which could
      prevent impairment of central nervous system function caused by the disease. Therefore, an
      early diagnosis of GLUT1-DS for its treatment is crucial.

      Currently, the disease is very difficult to diagnose correctly and in a timely manner. The
      current diagnosis practice requires a lumbar puncture in order to determine if
      hypoglycorrhachia occurs. The diagnosis result is then supported by the detection of a
      heterozygous pathogenic variant in SLC2A1 gene. This diagnosis procedure is time consuming,
      expensive, and requires a geneticist's data interpretation. Currently, ketogenic diet therapy
      is the most efficient therapy for GLUT1-DS.

      METAglut1 is a first-in-kind IVD device used to aid in the diagnosis of the GLUT1 Deficiency
      Syndrome (GLUT1-DS) by quantifying the cell surface expression level of the glucose
      transporter 1 (GLUT1) on circulating human red blood cells. The METAglut1 IVD is primarily
      intended for use in pediatric patients older than 3 months, of both sexes, of any ethnic
      origin. The METAglut1 IVD may also be used to aid in the diagnosis of GLUT1-DS in adults with
      late onset symptoms.

      The METAglut1 IVD is authorized for marketing in the European Union pursuant to the CE mark
      and is currently being distributed in France.

      The study aims to validate the diagnostic performances of METAglut1. It will last for 2
      years, more than 40 centers will participate in the study across France. Up to 3,000 patients
      with symptoms compatible with GLUT1-DS will be included prospectively; each of them will be
      tested for METAglut1, in parallel and blindly of the reference strategy. The METAglut1 test
      is performed by Laboratoire CERBA (Saint-Ouen l'Aumône, France). A retrospective cohort of
      already diagnosed patients will also be analyzed to add more data. Concordance analysis with
      the glycorrhachia, the first biochemical dosage involved in the reference strategy, will be
      performed, and overall diagnostic performances of METAglut1 calculated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The METAglut1 test is performed on each patient, in parallel and blindly of the reference diagnostic strategy which is performed through the current practice.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The METAglut1 test is performed blindly of the reference strategy. METAglut1's result masking is maintained for the investigator on the one hand, and the glycorrhachia value masking is maintained for the centralized testing laboratory in charge of METAglut1 on the other hand.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance analysis of METAglut1 and glycorrhachia</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>This analysis will be performed on patients with a diagnosis of certainty, either positive or negative, in the prospective cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, positive and negative predictive values of METAglut1</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>These analysis will be performed on patients with a diagnosis of certainty in the prospective cohort.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sensitivity, specificity of METAglut1</measure>
    <time_frame>Up to 6 moths</time_frame>
    <description>These analysis will be performed on patients with a diagnosis of certainty in the retrospective cohort.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to diagnosis</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The time between clinical suspicion of GLUT1-DS and diagnosis will be calculated and compared between different diagnostic strategies</description>
  </other_outcome>
  <other_outcome>
    <measure>Health technology assessment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Health technology assessment will be performed on patients included in the study</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Glut1 Deficiency Syndrome</condition>
  <condition>De Vivo Disease</condition>
  <condition>Seizures</condition>
  <condition>Movement Disorders</condition>
  <condition>Intellectual Disability</condition>
  <condition>Ataxia</condition>
  <arm_group>
    <arm_group_label>Patients for METAglut1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.
Already diagnosed patients are included retrospectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>METAglut1</intervention_name>
    <description>A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.</description>
    <arm_group_label>Patients for METAglut1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical suspicion of the GLUT1 Deficiency Syndrome

        Exclusion Criteria:

          -  Sickle cell disease S/S

          -  Abnormal imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanny Mochel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent Petit, DVM, PhD</last_name>
    <phone>+33961626517</phone>
    <email>vincent.petit@metafora-biosystems.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon Nizou, Engineer</last_name>
    <phone>+33961636517</phone>
    <email>manon.nizou@metafora-biosystems.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe VERNY, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Loïc DE PONTUAL, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Garche</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nouha ESSID, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline SEVIN, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Agathe ROUBERTIE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécilia MARELLI-TOSI, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fanny Mochel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Odile BOESPFLUG-TANGUY, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diane DOUMMAR, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Tarbes - CH Bigorre</name>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Coralie JACQUET, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.metafora-biosystems.com</url>
    <description>METAglut1's project website</description>
  </link>
  <reference>
    <citation>Gras D, Cousin C, Kappeler C, Fung CW, Auvin S, Essid N, Chung BH, Da Costa L, Hainque E, Luton MP, Petit V, Vuillaumier-Barrot S, Boespflug-Tanguy O, Roze E, Mochel F. A simple blood test expedites the diagnosis of glucose transporter type 1 deficiency syndrome. Ann Neurol. 2017 Jul;82(1):133-138. doi: 10.1002/ana.24970.</citation>
    <PMID>28556183</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>October 25, 2018</last_update_submitted>
  <last_update_submitted_qc>October 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Carbohydrate Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

